Bafna Pharmaceuticals Ltd

📈 Bafna Pharmaceuticals Reports Growth: Key Financial Highlights for Q2 & H1 2025

- Property, Plant & Equipment rose to ₹6,500.09 lakhs (Sep 2025) from ₹5,877.99 lakhs (Mar 2025), signaling capacity expansion.

- Total assets grew to ₹16,068.27 lakhs (Sep 2025) vs. ₹15,307.91 lakhs (Mar 2025).

- Q2 total income: ₹3,664.79 lakhs; H1 total income: ₹7,186.75 lakhs.

- Q2 profit before tax: ₹312.49 lakhs; H1 profit before tax: ₹651.38 lakhs.

- Q2 EPS: ₹1.32 (basic/diluted); H1 EPS: ₹2.75 (basic/diluted).

- Net cash flow from operations (H1): ₹931.25 lakhs.

- Auditors flagged non-receipt of foreign currency receivables (₹213 lakhs) and adjusted Income Tax Refund (₹45.17 lakhs) against demands.

- Business focus: Solely pharmaceutical formulations manufacturing (per Indian Accounting Standard 108).